Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Gut

No studies found 1 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Serious adverse events · people with surgically‐induced remission in Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)

Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.99 [0.39, 2.5]
1 study · 155 participants
Low